Search

Your search keyword '"McCutcheon, Keir"' showing total 219 results
Start Over Author "McCutcheon, Keir"
219 results on '"McCutcheon, Keir"'

2. ShOckwave ballooN or Atherectomy with Rotablation in calcified coronary artery lesions: Design and rationale of the SONAR trial

Author

Bennett, Johan, McCutcheon, Keir, Ameloot, Koen, Vanhaverbeke, Maarten, Lesizza, Pierluigi, Castaldi, Gianluca, Adriaenssens, Tom, Minten, Lennert, Palmers, Pieter-Jan, de Hemptinne, Quentin, de Wilde, Willem, Ungureanu, Claudiu, Vandeloo, Bert, Colletti, Giuseppe, Coussement, Patrick, Van Mieghem, Nicolas M., and Dens, Jo

Published
2024
Full Text
View/download PDF

6. An interventional sheep model of severe aortic valve stenosis hemodynamics for the evaluation of alterations in coronary physiology and microvascular function

Author

Minten, Lennert, primary, Langenaeken, Tom, additional, McCutcheon, Keir, additional, Bennett, Johan, additional, Van Hecke, Manon, additional, Algoet, Michiel, additional, Bézy, Stéphanie, additional, Duchenne, Jürgen, additional, Puvrez, Alexis, additional, Wouters, Laurine, additional, Voigt, Jens-Uwe, additional, Adriaenssens, Tom, additional, Desmet, Walter, additional, Sinnaeve, Peter, additional, Verbrugghe, Peter, additional, Oosterlinck, Wouter, additional, Claus, Piet, additional, Meuris, Bart, additional, and Dubois, Christophe, additional

Published
2024
Full Text
View/download PDF

8. Platinum chromium everolimus-eluting stents for the treatment of (complex) coronary artery disease; from SYNERGY™ to the MEGATRON™.

Author

Frederiks, Pascal, Castaldi, Gianluca, McCutcheon, Keir, and Bennett, Johan

Subjects
CORONARY artery disease, SURGICAL stents, CHROMIUM, PLATINUM, RADIOPACITY
Abstract

Introduction: The introduction of drug-eluting coronary stents (DES) into clinical practice in 2002 represented a major milestone in the treatment of obstructive coronary artery disease. Over the years, significant advances in polymer coating and in antiproliferative agent technology have further improved the safety and clinical performance of newer-generation DES. Areas covered: Development of platinum chromium (PtCr) alloys with high radial strength and high radiopacity have enabled the design of new, thin-strut, flexible, and highly trackable stent platforms, while simultaneously improving stent visibility. These advances have facilitated complex percutaneous treatment of a diverse population of patients in clinical practice. This review will provide an overview of the evolution in PtCr everolimus-eluting stents from PROMUS Element™ to SYNERGY™ to the recently introduced SYNERGY MEGATRON™. The clinical data will be summarized and put into perspective, especially focusing on the role of the SYNERGY™ and MEGATRON™ platforms in the treatment of complex coronary artery disease and high-risk patients. Expert opinion: The SYNERGY™ stent demonstrates favorable clinical efficacy and safety outcome data, and whilst the clinical data on MEGATRON™ are sparse, early experience is promising. The specific overexpansion capabilities, visibility, and radial strength of the MEGATRON™ are attractive features for complex coronary interventions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Heart Failure-Related Outcomes in Patients with Left Ventricular Dysfunction Undergoing Percutaneous Chronic Total Occlusion Revascularization

Author

Lesizza, Pierluigi, primary, Minten, Lennert, primary, Poels, Ella, primary, Vanhaverbeke, Maarten, primary, Castaldi, Gianluca, primary, McCutcheon, Keir, primary, Cottens, Daan, primary, Zivelonghi, Carlo, primary, Agostoni, Pierfrancesco, primary, Dubois, Christophe, primary, Dens, Jo, primary, and Bennett, Johan, primary

Published
2023
Full Text
View/download PDF

13. Optimal Measurement of Coronary Flow and Microvascular Function in Animals and Humans

Author

Minten, Lennert, primary, Algoet, Michiel, additional, Bennett, Johan, additional, Oosterlinck, Wouter, additional, Meuris, Bart, additional, Langenaeken, Tom, additional, Bézy, Stephanie, additional, Wouters, Laurine, additional, Duchenne, Jürgen, additional, Puvrez, Alexis, additional, De Groote, Senne, additional, Lesizza, Pierluigi, additional, Frederiks, Pascal, additional, De Vos, Laurens, additional, Adriaenssens, Tom, additional, Sinnaeve, Peter, additional, Desmet, Walter, additional, McCutcheon, Keir, additional, and Dubois, Christophe, additional

Published
2023
Full Text
View/download PDF

21. Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation

Author

McCutcheon, Keir, Vanhaverbeke, Maarten, Dabin, Jérémie, Pauwels, Ruben, Schoonjans, Werner, Desmet, Walter, and Bennett, Johan

Subjects
cardiac catheterization, Article Subject, X-Rays, Coronary Angiography, Radiation Dosage, radiation, Percutaneous Coronary Intervention, Treatment Outcome, Coronary Occlusion, Risk Factors, RC666-701, Occupational Exposure, Chronic Disease, Diseases of the circulatory (Cardiovascular) system, Humans, Radiology, Nuclear Medicine and imaging, Prospective Studies, Cardiology and Cardiovascular Medicine, risk, Research Article
Abstract

Background. The MAVIG X-ray protective drape (MXPD) has been shown to reduce operator radiation dose during percutaneous coronary interventions (PCI). Whether MXPDs are also effective in reducing operator radiation during chronic total occlusion (CTO) PCI, often with dual access, is unknown. Methods. We performed a prospective, randomized-controlled study comparing operator radiation dose during CTO PCI (n = 60) with or without pelvic MXPDs. The primary outcomes were the difference in first operator radiation dose (μSv) and relative dose of the first operator (radiation dose normalized for dose area product) at the level of the chest in the two groups. The effectiveness of MXPD in CTO PCI was compared with non-CTO PCI using a patient-level pooled analysis with a previously published non-CTO PCI randomized study. Results. The use of the MXPD was associated with a 37% reduction in operator dose (weighted median dose 26.0 (IQR 10.00–29.47) μSv in the drape group versus 41.8 (IQR 30.82–60.59) μSv in the no drape group; P < 0.001 ) and a 60% reduction in relative operator dose (median dose 3.5 (IQR 2.5–5.4) E/DAPx10−3 in the drape group versus 8.6 (IQR 4.2–12.5) E/DAPx10−3 in the no drape group; P = 0.001 ). MXPD was equally effective in reducing operator dose in CTO PCI compared with non-CTO PCI ( P value for interaction 0.963). Conclusions. The pelvic MAVIG X-ray protective drape significantly reduced CTO operator radiation dose. This trial is clinically registered with https://www.clinicaltrials.gov (unique identifier: NCT04285944).

Published
2021

22. Arteriovenous Fistulae in Chronic Kidney Disease and the Heart: Physiological, Histological, and Transcriptomic Characterization of a Novel Rat Model

Author

Van den Eynde, Jef, primary, Jacquemyn, Xander, additional, Cloet, Nicolas, additional, Noé, Dries, additional, Gillijns, Hilde, additional, Lox, Marleen, additional, Gsell, Willy, additional, Himmelreich, Uwe, additional, Luttun, Aernout, additional, McCutcheon, Keir, additional, Janssens, Stefan, additional, and Oosterlinck, Wouter, additional

Published
2022
Full Text
View/download PDF

26. Angiographic predictors of aberrant circumflex artery during cardiac catheterization

Author

Triantafyllis, Andreas S., primary, van Nunen, Lokien X., additional, Lesizza, Pierluizi, additional, Pagourelias, Efstathios D., additional, Kalogeris, Aimilianos, additional, Bouwmeester, Sjoerd, additional, Tsinivizov, Pavlos, additional, Kontogiannis, Nestoras, additional, Giannakopoulos, Andreas, additional, Poulimenos, Leonidas E., additional, Bennett, Johan, additional, Teeuwen, Koen, additional, Kyfnidis, Konstantinos, additional, Desmet, Walter, additional, Tonino, Pim A. L., additional, and McCutcheon, Keir, additional

Published
2022
Full Text
View/download PDF

37. A Randomized Controlled Trial

Author

McCutcheon, Keir, Vanhaverbeke, Maarten, Pauwels, Ruben, Dabin, Jérémie, Schoonjans, Werner, Bennett, Johan, Adriaenssens, Tom, Dubois, Christophe, Sinnaeve, Peter, and Desmet, Walter

Subjects
radiation, cardiac catheterization, percutaneous coronary intervention, risk
Abstract

Background Interventional cardiologists are occupationally exposed to high doses of ionising radiation. The MAVIG X-ray Protective Drape (MXPD) is a commercially available light-weight, lead-free shield placed over the pelvic area of patients in order to minimize operator radiation dose. The aim of this study was to examine the efficacy of the MXPD during routine cardiac catheterization including percutaneous coronary interventions (PCI). Methods We performed a prospective, randomized-controlled study comparing operator radiation dose during cardiac catheterization and PCI (n=632) with or without pelvic MXPD. We measured operator radiation dose at four sites: left eye, chest, left ring finger and right ring finger. The primary outcomes were the difference in first operator radiation dose (µSv) and relative dose of the first operator (radiation dose normalized for dose area product) at the level of the chest in the two groups. Results The use of the MXPD was associated with a 50% reduction in operator radiation dose (median dose 30.5 (IQR 23.0-39.7) µSv in No Drape group, versus 15.3 (IQR 11.1-20.0) µSv in the Drape group; P Conclusions The pelvic MXPD significantly reduces first operator radiation dose during routine cardiac catheterization and PCI.

Published
2020

39. The coronary resorbable magnesium scaffold Magmaris: what we've learnt (so far...)

Author

Bennett, Johan and McCutcheon, Keir

Abstract

Bioresorbable scaffold (BRS) technology provides transient vessel support with drug-delivery capability without the long-term limitations of the permanent metallic drug-eluting stents (DES). Numerous scaffolds have been developed and investigated by device manufacturers, many of which, due to device deficiencies, have fallen by the way side. This short review will focus on the resorbable magnesium scaffold "Magmaris", the only metallic bioresorbable scaffold currently available, providing an evaluation of the most up to date clinical data whilst also briefly highlighting learning points regarding the ideal patient and lesion choice and optimal implantation technique. ispartof: Minerva Cardioangiol ispartof: location:Italy status: Published online

Published
2020

42. iFR uncovers profound but mostly reversible ischemia in CTOs and helps to optimize PCI results

Author

Kayaert, Peter, primary, Coeman, Mathieu, additional, Drieghe, Benny, additional, Bennett, Johan, additional, McCutcheon, Keir, additional, Dens, Jo, additional, Ungureanu, Claudiu, additional, Zivelonghi, Carlo, additional, Agostoni, Pierfrancesco, additional, Bataille, Yoann, additional, de Hemptinne, Quentin, additional, Gevaert, Sofie, additional, De Pauw, Michel, additional, and Haine, Steven, additional

Published
2020
Full Text
View/download PDF

48. Hybrid Myocardial Revascularization or Multivessel Minimally Invasive Direct Coronary Artery Bypass: Two Case Reports

Author

Van den Eynde, Jef, Bennett, Johan, McCutcheon, Keir, Adriaenssens, Tom, Verbelen, Tom, Jacobs, Steven, and Oosterlinck, Wouter

Abstract

https://www.scitechnol.com/peer-review/hybrid-myocardial-revascularization-or-multivessel-minimally-invasive-direct-coronary-artery-bypass-two-case-reports-unwv.php?article_id=10342 ispartof: International Journal of Cardiovascular Research vol:8 issue:4 pages:1-3 status: published

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results